The ACTG Network as a whole is excited to announce the publication and presentation of results from the REPRIEVE trial which found a 35 percent reduction in the risk of cardiovascular events among people living with HIV who took a daily statin compared to those receiving placebo over a five-year period. The findings were published in the New England Journal of Medicine and presented at the 2023 International AIDS Society conference earlier this year in Brisbane, Australia. Please extend a hearty congratulations to our colleagues who worked on the study and read the press release here.
Additionally, our very own Thomas Villa, a local advocate and avid research participant, was featured in the ACTG's international newsletter about his perspectives on partner safety and analytic treatment interruption (ATI) which refers to the strategy of stopping approved HIV suppression treatment to investigate the effectiveness of new HIV medications in development. Community members like Tom advocate for the consideration of intimate partners as this population could be affected by their lovers' necessary involvement with clinical trials. On his continued involvement in HIV clinical research, Tom shared:
“When I volunteer to participate in early-phase clinical trials, I see myself not
as some hapless test subject but as a co-investigator, one whose role necessarily
differs from those of the Principal Investigator and scientific team but is none-
theless essential to the research. One who believes the research is of sufficient
value that I am willing to put some skin in the game, so to speak. And we all
know that many clinical trials involve more than mere skin. As a result, I do
not take the decision to participate lightly but rather approach it in a deliberate
manner similar to that for any weighty decision.” To read more of Tom's
reflections, click here.
|